Ligand Pharmaceuticals

What Ligand Pharmaceuticals does

Ligand Pharmaceuticals is a publicly traded biopharmaceutical royalty aggregator (NASDAQ: LGND) founded in 1987 and headquartered in Jupiter, Florida. The company provides strategic capital to biopharmaceutical companies to finance and advance late-stage clinical development programs, and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with more than 200 commercial, clinical, and preclinical-stage assets following the July 2026 acquisition of XOMA Royalty. Ligand generates revenue primarily through royalties on commercial products developed by partner companies, including key partnered assets such as FILSPARI (9% royalty from Travere for IgA nephropathy and FSGS), OHTUVAYRE (3% from Merck for COPD), VABYSMO (0.50% from Roche), and KYPROLIS (1.5-3% from Amgen).

Ligand operates two proprietary technology platforms. Captisol® is a chemically modified cyclodextrin designed to optimize solubility and stability of drugs, used by partners including Amgen, Merck, Pfizer, Takeda, and Gilead (the latter for Remdesivir for COVID-19). Captisol is incorporated in approximately 17 approved therapies and generated approximately $40 million in royalties in 2025, up 30% year-over-year. NITRICIL™ is a proprietary nitric oxide-based technology platform available for out-license with broad applicability in drug development. The company also conducts supplementary investment activities including royalty financing, project finance, and platform technology acquisitions.

In 2025, Ligand reported total revenue of $268 million (up 60% year-over-year) and royalty revenue of $161 million (up 48% year-over-year), with $124.5 million in GAAP net income compared to a $4 million loss in 2024. Q2 2026 revenue reached $63.7 million (up 34% year-over-year). The company completed a $739 million acquisition of XOMA Royalty in July 2026 and a $700 million 0% convertible senior notes offering in June 2026 to fund inorganic growth. Ligand serves 100+ partner companies spanning multiple therapeutic areas including oncology, rare disease, infectious disease, pulmonology, ophthalmology, and cardiology, with a global operating footprint across the United States and Europe.

Name

Ligand Pharmaceuticals

Legal name

Ligand Pharmaceuticals Incorporated

Website

https://ligand.com

Company type

Public

Founded year

1987

Operating status

Operating

Headcount range

11–50 employees

Short description

Ligand Pharmaceuticals is a publicly traded biopharmaceutical royalty aggregator that provides strategic capital to biopharma companies and manages a diversified portfolio of over 200 royalty assets, with proprietary Captisol® and NITRICIL™ technology platforms and 40+ marketed partnered products.

Ownership category

akta.pro rank

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Royalty Revenue: Ligand generates revenue through royalties on commercial products developed by partner companies. Key royalty-generating products include Filspari (9% royalty from Travere), Ohtuvayre (3% from Merck), Kyprolis (1.5-3%), Vabysmo (0.50% from Roche), and over 40 other marketed products. Full-year 2025 royalty revenue was $161 million, up 48% year-over-year.
2. Captisol Technology Royalties: Revenue from Captisol-enabled drug formulations, with approximately $40 million in royalties in 2025, up 30% year-over-year. Captisol is used in 17 approved therapies.
3. Acquisition Royalties (XOMA): Following the July 2026 XOMA Royalty acquisition, Ligand gained seven commercial products including VABYSMO (Roche), OJEMDA (Servier), and MIPLYFFA (Zevra Therapeutics), plus 14 late-stage development programs and over 100 additional assets.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Ligand Pharmaceuticals is a biopharmaceutical royalty aggregator that provides strategic capital to biopharmaceutical companies to finance and advance late-stage clinical development programs. The company manages one of the largest and most diversified portfolios of biopharmaceutical royalties with over 200 commercial, clinical, and preclinical-stage programs, and licenses proprietary technology platforms (Captisol® and NITRICIL™) to pharmaceutical partners. Revenue is generated primarily through royalty streams on approved drugs commercialized by partners such as Merck, Roche, Amgen, and Travere.

Product overview

Ligand Pharmaceuticals is a leading royalty aggregator that partners with biopharmaceutical companies to finance and advance late-stage clinical development programs. The company operates primarily as an investment platform that acquires and manages royalty assets rather than developing drugs directly. Its core offerings include technology platforms (Captisol® for drug solubility and NITRICIL™ for nitric oxide-based therapeutics available for out-license), and a diversified royalty portfolio spanning more than 200 commercial, clinical, and preclinical-stage assets across multiple therapeutic areas including oncology, rare disease, infectious disease, pulmonology, ophthalmology, and cardiology. Key commercial partnered products include FILSPARI (kidney disease), VABYSMO (ophthalmology), OHTUVAYRE (COPD), KYPROLIS (oncology), and QARZIBA (rare oncology), among approximately 40+ marketed products generating royalties. Investment strategies include Royalty Monetization, M&A, Project Finance, and Platform Technology Acquisitions.

Differentiator

Problem solved

Functional benefit

Brands

• Captisol: Chemically modified cyclodextrin technology platform designed to optimize solubility and stability of drugs. Used by partners including Amgen, Merck, Pfizer, Takeda, and Gilead.
• NITRICIL

Products and services

• Captisol®

Quantifiable outcome

• Full-year 2025 royalty revenue of $161 million, up 48% year-over-year
• +3 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• XOMA Royalty CorporationcoreStrategic or Co-development Partner · 14 July 2026Acquired by Ligand for $739 million ($39 per share). Adds 7 commercial products (VABYSMO, OJEMDA, MIPLYFFA), 14 late-stage development programs, and over 100 additional assets, more than doubling Ligand's portfolio to over 200 royalty assets. Includes CVR tied to Tremfya litigation proceeds.
• APEIRON Biologics AGcoreStrategic or Co-development Partner · 1 July 2024Acquired by Ligand for $100 million in July 2024. Includes rights to QARZIBA (dinutuximab beta), a treatment for high-risk neuroblastoma approved by EMA in 2017 and marketed in 35 countries. Ligand also invested up to $4 million in APEIRON's spin-off invIOs Holding AG for immuno-oncology development.
• MerckcoreStrategic or Co-development PartnerKey royalty partner for OHTUVAYRE (Ensifentrine) for COPD - 3% royalty. Also for CAPVAXIVE and VAXNEUVANCE pneumococcal vaccines - low-single-digit royalties. Q4 2025 sales of Ohtuvayre reached $196 million, up 45% sequentially.
• Travere TherapeuticscoreStrategic or Co-development PartnerPartner for FILSPARI (sparsentan) for IgA nephropathy and FSGS - 9% royalty on worldwide net sales. FDA granted full approval for FSGS in April 2026, expanding addressable population to over 100,000 US patients.
• RochecoreStrategic or Co-development PartnerRoyalty interest in VABYSMO (faricimab) for wet AMD and diabetic macular edema - 0.50% royalty. Vabysmo is a key royalty driver from XOMA acquisition.
• AmgencoreStrategic or Co-development PartnerRoyalty partner for KYPROLIS (carfilzomib) for relapsed/refractory multiple myeloma - 1.5-3% royalty.
• Palvella TherapeuticscoreStrategic or Co-development PartnerPartner for QTORIN Rapamycin program - 8-9.8% royalty. Programs in microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Estimated peak sales over $3 billion with ~$285 million potential annual free cash flow to Ligand.
• PfizercoreTechnology or IntegrationCaptisol platform partner using the technology to improve solubility of drug candidates. Also partner for DUAVEE (tiered low-single-digit royalty).
• GileadcoreTechnology or IntegrationCaptisol platform partner which used the technology to improve solubility for Remdesivir (VEKLURY) for COVID-19 treatment.
• Viking TherapeuticscoreStrategic or Co-development PartnerLicensing partner for VK2809 (3.5-7.5% royalty for MASH) and VK0214 (undisclosed royalty for X-ALD). Ligand filed notice in May 2026 alleging material breach of 2014 licensing agreement regarding TRβ program.
• ArecorminorStrategic or Co-development PartnerRoyalty financing agreement tied to royalties and milestones from AT220 and AT292 programs. Received $0.5 million milestone in March 2026 with additional $3 million in potential milestones.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• HealthCare Royalty Partners: A private healthcare royalty financing firm founded by Ligand CEO Todd Davis. Operates the same royalty-financing and structured-capital model as Ligand and was historically a direct competitor for late-stage biopharma royalty transactions.
• HealthCare Royalty Partners Fund IV (HCR): Continuation vehicles and successor funds of HealthCare Royalty Partners continue to compete for biopharma royalty deals using the same royalty aggregator thesis pioneered by Todd Davis. They are a direct peer in target assets and deal sourcing.
• DRI Capital: Canadian-based royalty aggregator that acquires and manages royalty interests in late-stage biopharmaceutical products. Operates a near-identical royalty aggregation model and competes for similar high-quality biopharma royalty streams.
• XOMA Royalty Corporation: Pre-acquisition, XOMA was a directly comparable royalty aggregator managing royalty interests in commercial and development-stage assets (Vabysmo, Ojemda, Miplyffa, among others). It was Ligand's most direct scaled peer and its 2026 acquisition shows how directly the two competed for similar assets.
• Royalty Pharma: The largest publicly traded pharmaceutical royalty buyer (NASDAQ: RPRX), directly comparable in business model: acquires royalty interests in marketed and late-stage biopharma products, then collects long-duration cash flows. Royalty Pharma is the most direct competitor for high-quality biopharma royalty streams.

Emerging players

• OMERS Life Sciences: Pension-backed investor that has been actively deploying capital into biopharma royalty and structured finance transactions, increasingly overlapping Ligand's late-stage financing and royalty aggregation focus.
• Aisling Capital: Healthcare-focused investment firm that participates in biopharma structured financings and royalty deals alongside players like Ligand. Smaller and more focused, but competes for similar late-stage biopharma opportunities.
• Pharmakon Advisors: Specialized structured capital provider to late-stage biopharma companies, offering royalty and debt financings that closely mirror Ligand's project finance and royalty monetization strategy.

Broad incumbents

• OrbiMed: Global healthcare investment firm with dedicated royalty, structured finance, and credit strategies that overlap with Ligand's business model. OrbiMed is broader in mandate (private equity, venture, royalty, credit) but is a meaningful competitor for biopharma royalty financings.
• Blackstone Life Sciences: Life sciences arm of Blackstone deploying $1B+ biopharma development capital, including royalty and structured financings overlapping Ligand's project finance and royalty monetization strategies. SVP Peter Renehan at Ligand was previously a Principal at Blackstone Life Sciences.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ligand-pharmaceuticals
• Xx.com/Ligand_LGND

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries4 records

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A14 records

Investments23 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ligand Pharmaceuticals